Rivaroxaban (Xarelto, BAY59-7939)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Venous Thrombosis
Conditions
Venous Thrombosis, Deep Vein Thrombosis
Trial Timeline
May 1, 2009 → Jun 1, 2011
NCT ID
NCT00786422About Rivaroxaban (Xarelto, BAY59-7939)
Rivaroxaban (Xarelto, BAY59-7939) is a phase 2 stage product being developed by Johnson & Johnson for Venous Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00786422. Target conditions include Venous Thrombosis, Deep Vein Thrombosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00786422 | Phase 2 | Completed |
Competing Products
20 competing products in Venous Thrombosis